載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.73
−US$0.02 · -1.14%
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
前收盤價
US$1.73
−US$0.02 · -1.14%
盤前
US$1.73
US$0.00 · 0.00%
10月12日 上午7:58 ET
盤中時間採用ET。市場資料可能有所延遲。
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
日內區間
目前US$1.73
52週區間
目前US$1.73
盤中時間採用ET。市場資料可能有所延遲。
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
日內區間
目前US$1.73
52週區間
目前US$1.73
營業利益
淨利
| 項目（CAD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 8.37萬 CAD | 14.5萬 CAD | 11.41萬 CAD | 4.3萬 CAD |
| 毛利 | — | −8.37萬 CAD | −14.5萬 CAD | −11.41萬 CAD | −4.3萬 CAD |
| 研究與開發 | 1390.72萬 CAD | 1565.94萬 CAD | 800.06萬 CAD | 1642.58萬 CAD | 688.29萬 CAD |
| 銷售、一般及管理費用 | 1117.2萬 CAD | 917.22萬 CAD | 963.26萬 CAD | 628.27萬 CAD | 598.28萬 CAD |
| 營業費用 | 2507.93萬 CAD | 2483.15萬 CAD | 1763.32萬 CAD | 2270.84萬 CAD | 1286.57萬 CAD |
| 利息收入 | 33.34萬 CAD | 81.21萬 CAD | 55.01萬 CAD | 19.96萬 CAD | 2.96萬 CAD |
| 利息支出 | — | — | — | 51.01萬 CAD | — |
| 折舊和攤銷 | 5.58萬 CAD | 8.37萬 CAD | 14.5萬 CAD | 11.41萬 CAD | 4.3萬 CAD |
| 營業利益 | −2507.93萬 CAD | −2491.53萬 CAD | −1777.82萬 CAD | −2282.25萬 CAD | −1290.87萬 CAD |
| 淨利 | −4411.73萬 CAD | −2398.98萬 CAD | −2238.4萬 CAD | −2054萬 CAD | −1282.34萬 CAD |
公司資料更新於 2026年10月12日。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
